Trial · NCT07017439
Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period
NCT07017439, Phase 3, Not yet recruiting, University of Manitoba
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period. Trials, record NCT07017439. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07017439
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period
- NCT number
- NCT07017439
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 50 participants, estimated
- Lead sponsor
- University of Manitoba
- Conditions
- Benign Prostate Hypertrophy(BPH)
- Interventions
- Beta-3 agonists (Mirabegron/Myrbetriq), Placebo group post rezum
- First posted
- 2025-06-12
- Last updated
- 2025-06-12
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in symptom scores | Symptom scores will be taken pre-op at time of consultation and at 1, 2 and 4 week follow-up | Change in the following symptoms scores IPSS-QOL (higher scores indicate worser outcomes) |
| Primary | Change in symptom scores | Symptom scores will be taken pre-op at time of consultation and at 1, 2 and 4 week follow-up | Change in OABSS symptom scores. (higher scores indicate worse outcomes) |
| Secondary | Rate of successful catheter removal | Will be measured at the scheduled trial of void either 1 week or 2 weeks post-op | Rates of successful trial of voids(TOV) post-op will be captured. If the catheter is removed it is a succesful TOV, if it is not it is considered a failed TOV. |
| Secondary | Adverse events | Possible adverse will be captured at time of consultation pre-op and at 1, 2 and 4 week follow-ups. | Adverse events will be captured and recorded post-op. |
| Secondary | rate of Qmax improvement | Uroflow parameters will be captured at time of consultation pre-op and the 4 week follow-up post-op. | Uroflow parameter |
| Secondary | rates of post void residual | Uroflow parameters will be captured at time of consultation pre-op and the 4 week follow-up post-op. | Uroflow test |
| Secondary | time to max flow | Uroflow parameters will be captured at time of consultation pre-op and the 4 week follow-up post-op. | Uroflow test |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07017439
GET https://conductscience.org/api/trials/v1/NCT07017439/registered